Tyrosine kinase inhibitors in glioblastoma (WP5494)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
"Therapeutic tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies in glioblastoma anti-EGFR mAbs bind the EGFR extracellular domain, preventing EGFR dimerization and subsequent activation. Tyrosine kinase inhibitors (TKIs) target the intracellular TK domain, blocking subsequent receptor tyrosine kinase pathways (RTKs)" From Figure F3 in https://pmc.ncbi.nlm.nih.gov/articles/PMC10967338. Derived from https://pfocr.wikipathways.org/figures/PMC10967338__antibodies-13-00025-g003.html

Authors

Eric Weitz and Egon Willighagen

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Cell Type Ontology

glial cell

Pathway Ontology

drug pathway

Disease Ontology

glioblastoma

Participants
Query Drugst.One

Label Type Compact URI Comment
Cetuximab Metabolite chebi:PA10040
Panitumumab Metabolite chebi:PA162373091
Erlotinib Metabolite chebi:114785
Gefitinib Metabolite chebi:49668
Lapatinib Metabolite chebi:49603
Dacomitinib Metabolite chebi:132268
Afatinib Metabolite chebi:61390
Neratinib Metabolite chebi:61397
PIP3 Metabolite chebi:16618
PIP2 Metabolite chebi:77276
JAK1 GeneProduct ensembl:ENSG00000162434
JAK2 GeneProduct ensembl:ENSG00000096968
JAK3 GeneProduct ensembl:ENSG00000105639
TYK2 GeneProduct ensembl:ENSG00000105397
PDK1 GeneProduct ensembl:ENSG00000152256
STAT3 GeneProduct ensembl:ENSG00000168610
AKT1 GeneProduct ensembl:ENSG00000142208
AKT2 GeneProduct ensembl:ENSG00000105221
AKT3 GeneProduct ensembl:ENSG00000117020
TSC1 GeneProduct ensembl:ENSG00000165699
TSC2 GeneProduct ensembl:ENSG00000103197
RHEB GeneProduct ensembl:ENSG00000106615
MTOR GeneProduct ensembl:ENSG00000198793
RPTOR GeneProduct ensembl:ENSG00000141564
EREG GeneProduct ensembl:ENSG00000124882 'EPR' originally
BTC GeneProduct ensembl:ENSG00000174808
TGFA GeneProduct ensembl:ENSG00000163235
EGF GeneProduct ensembl:ENSG00000138798
KRAS GeneProduct ensembl:ENSG00000133703
HRAS GeneProduct ensembl:ENSG00000174775
NRAS GeneProduct ensembl:ENSG00000213281
SOS1 GeneProduct ensembl:ENSG00000115904
SOS2 GeneProduct ensembl:ENSG00000100485
GRB2 GeneProduct ensembl:ENSG00000177885
PTEN GeneProduct ensembl:ENSG00000171862
RAF1 GeneProduct ensembl:ENSG00000132155
MAP2K1 GeneProduct ensembl:ENSG00000107356
MAP2K2 GeneProduct ensembl:ENSG00000101418
MAP2K3 GeneProduct ensembl:ENSG00000107958
MAP2K4 GeneProduct ensembl:ENSG00000115669
MAP2K5 GeneProduct ensembl:ENSG00000138015
MAP2K6 GeneProduct ensembl:ENSG00000129652
MAP2K7 GeneProduct ensembl:ENSG00000118907

References

  1. vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target. Manzanares-Guzmán A, Lugo-Fabres PH, Camacho-Villegas TA. Antibodies (Basel). 2024 Mar 18;13(1):25. PubMed Europe PMC Scholia